CD274 and small cell lung carcinoma: Notably, while SCLC tumors with TMB >10 mutations/Mb may exhibit sensitivity to immune checkpoint inhibitors (PD-1/PD-L1 inhibitors), elevated TMB does not invariably predict enhanced therapeutic efficacy.